Sökning: id:"swepub:oai:gup.ub.gu.se/252409" >
Exenatide improves ...
Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.
-
van Raalte, Daniël H (författare)
-
Bunck, Mathijs C (författare)
-
Smits, Mark M (författare)
-
visa fler...
-
Hoekstra, T (författare)
-
Cornér, Anja (författare)
-
Diamant, Michaela (författare)
-
- Eliasson, Björn, 1959 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
Marja-RiittaTaskinen, (författare)
-
Heine, Robert J (författare)
-
- Smith, Ulf, 1943 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
HanneleYki-Järvinen, (författare)
-
Mari, Andrea (författare)
-
visa färre...
-
(creator_code:org_t)
- 2016
- 2016
- Engelska.
-
Ingår i: European journal of endocrinology. - 1479-683X. ; 175:4, s. 345-52
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Glucagon-like peptide (GLP)-1 receptor agonist treatment improves β-cell function. In this study, we investigated whether the improvements are sustained during a 3-year treatment period.Sixty-nine metformin-treated type 2 diabetes patients were randomised to the GLP1 receptor agonist, exenatide (EXE) twice daily (BID) or to insulin glargine (GLAR). β-cell function parameters were derived using the Mari model from standardised breakfast and lunch meals that were administered before treatment, and after 1 and 3years of treatment. EXE was administered before breakfast.Fifty-nine (EXE: n=30; GLAR: n=29) and thirty-six (EXE: n=16; GLAR: n=20) patients completed the meal at 1- and 3-year treatment respectively. After 3years, groups had comparable glycaemic control (HbA1c: EXE 6.6±0.2% and GLAR 6.9±0.2%; P=0.216). Compared with GLAR, at 1 and 3years, EXE induced a stronger reduction in post-breakfast glucose concentrations (P<0.001), with lower C-peptide levels (P<0.001). Compared with GLAR, EXE increased insulin secretion at 8mmol/L glucose throughout the study period (P<0.01). Both treatments improved β-cell glucose sensitivity after 1-year treatment. However, only EXE treatment sustained this improvement for 3years. No consistent changes in other β-cell parameters including rate sensitivity and potentiation were observed.Compared with GLAR, EXE improved the parameters of β-cell function, especially insulin secretion at 8mmol/L glucose and β-cell glucose sensitivity, which was sustained during the 3-year treatment period.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- Blood Glucose
- Diabetes Mellitus
- Type 2
- drug therapy
- physiopathology
- Female
- Humans
- Hypoglycemic Agents
- pharmacology
- therapeutic use
- Insulin-Secreting Cells
- drug effects
- physiology
- Male
- Middle Aged
- Peptides
- pharmacology
- therapeutic use
- Postprandial Period
- Treatment Outcome
- Venoms
- pharmacology
- therapeutic use
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
van Raalte, Dani ...
-
Bunck, Mathijs C
-
Smits, Mark M
-
Hoekstra, T
-
Cornér, Anja
-
Diamant, Michael ...
-
visa fler...
-
Eliasson, Björn, ...
-
Marja-RiittaTask ...
-
Heine, Robert J
-
Smith, Ulf, 1943
-
HanneleYki-Järvi ...
-
Mari, Andrea
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
European journal ...
- Av lärosätet
-
Göteborgs universitet